Ligand id: 9807

Name: TNT009

View interactive charts of activity data from GtoPdb and ChEMBL (where available) across species

Bioactivity Comments
Preclinical details of TNT009 in vitro activity are published in [4], and results from the first-in-human Phase 1 trial are reported in [2]. In kidney transplant patients, TNT009 (BIVV009) effectively blocks alloantibody-triggered complement pathway activation, but this fails to translate to therapeutic benefit in the short term [1]. Further studies are needed to fully evaluate the therapeutic value of complement pathway blockade in transplant patients.
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
complement C1s Hs Antibody Binding 9.6 pKd - 3
pKd 9.6 (Kd 2.6x10-10 M) [3]